These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1613698)

  • 1. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice.
    Morand EF; McCloud PI; Littlejohn GO
    J Rheumatol; 1992 May; 19(5):704-8. PubMed ID: 1613698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
    Ortendahl M; Schettler JD; Fries JF
    J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice.
    Buchbinder R; Hall S; Sambrook PN; Champion GD; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
    J Rheumatol; 1993 Apr; 20(4):639-44. PubMed ID: 8496857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
    Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
    J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis.
    Hoekstra M; van de Laar MA; Bernelot Moens HJ; Kruijsen MW; Haagsma CJ
    J Rheumatol; 2003 Nov; 30(11):2325-9. PubMed ID: 14677172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts.
    Wolfe F; Hawley DJ; Cathey MA
    J Rheumatol; 1990 Aug; 17(8):994-1002. PubMed ID: 1976811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
    O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
    Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The methotrexate therapeutic response in rheumatoid arthritis.
    Ortendahl M; Holmes T; Schettler JD; Fries JF
    J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.
    Islam MN; Alam MN; Haq SA; Moyenuzzaman M; Patwary MI; Rahman MH
    Bangladesh Med Res Counc Bull; 2000 Apr; 26(1):1-7. PubMed ID: 11192489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Favorable results of early 2nd-stage medication in rheumatoid arthritis].
    van Jaarsveld CH; van der Heide A
    Ned Tijdschr Geneeskd; 1997 Apr; 141(15):732-6. PubMed ID: 9213790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
    Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F; Michaud K; Stephenson B; Doyle J
    J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G; Aviña-Zubieta JA; Russell AS; Suarez-Almazor ME
    J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methotrexate and non-steroidal anti-inflammatory agent combination in rheumatoid arthritis].
    Bertin P; Carpentier N; Vergne P; Bonnet C; Bannwarth B; Dehais J; Treves R
    Therapie; 1997; 52(2):133-7. PubMed ID: 9231508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions.
    Kinder AJ; Hassell AB; Brand J; Brownfield A; Grove M; Shadforth MF
    Rheumatology (Oxford); 2005 Jan; 44(1):61-6. PubMed ID: 15611303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug.
    Prescrire Int; 2001 Apr; 10(52):36-9. PubMed ID: 11718154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H; Ohno S; Ishigatsubo Y
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.